Co-DiagnosticsCODX
CODX logo
Fair Value
US$10
Share price17 Aug
US$3.0869.2% undervalued intrinsic discount
Loading
1Y-64.10%
7D-13.73%

Decentralized Diagnostics Will Expand Global Infectious Disease Surveillance

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published
17 Aug 25
Views
17
Not Invested

Fair Value vs Share Price

US$10
vs US$3.0869.2% undervalued intrinsic discount
PastFuture-43m105m2014201720202023202520262028Revenue US$54.6mEarnings US$6.8m
278.9%
Revenue growth
12.4%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Co-Diagnostics

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet with moderate risk.

Market capUS$11.3m
PB0.7x
Estimated Growth63.4%
Dividend YieldN/A
Full analysis

CEO & management

Dwight Egan
CEO
2.3yrs
CEO Tenure

Operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.